Independent predictors of stroke in patients with atrial fibrillation: a systematic review
- PMID: 17679673
- DOI: 10.1212/01.wnl.0000267275.68538.8d
Independent predictors of stroke in patients with atrial fibrillation: a systematic review
Abstract
Background: Absolute stroke rates vary widely among patients with nonvalvular atrial fibrillation. To balance the benefits and risks of chronic antithrombotic prophylaxis, it is important to estimate the absolute risk of stroke for individual patients.
Methods: Systematic review of studies using multivariate regression techniques to identify independent risk factors for stroke in patients with atrial fibrillation was conducted, and reports of absolute stroke rates in subgroups of patients with these risk factors collected. A summary estimate of the relative risk associated with each independent risk factor was calculated using maximum likelihood methods.
Results: Seven studies (including six entirely independent cohorts) were identified. Prior stroke/TIA (relative risk 2.5, 95% CI 1.8 to 3.5), increasing age (relative risk 1.5 per decade, 95% CI 1.3 to 1.7), a history of hypertension (relative risk 2.0, 95% CI 1.6 to 2.5), and diabetes mellitus (relative risk 1.7, 95% CI 1.4 to 2.0) were the strongest, most consistent independent risk factors. Observed absolute stroke rates for nonanticoagulated patients with single independent risk factors were in the range of 6 to 9% per year for prior stroke/TIA, 1.5 to 3% per year for history of hypertension, 1.5 to 3% per year for age >75, and 2.0 to 3.5% per year for diabetes. Female sex was inconsistently associated with stroke risk, whereas the evidence was inconclusive that either heart failure or coronary artery disease is independently predictive of stroke.
Conclusions: Four clinical features (prior stroke/TIA, advancing age, hypertension, diabetes) are consistent independent risk factors for stroke in atrial fibrillation patients. Prior stroke/TIA is the most powerful risk factor and reliably confers a high stroke risk (>5% per year, averaging 10% per year). Absolute stroke rates associated with other individual risk factors are difficult to precisely estimate from available data.
Similar articles
-
Dipyridamole for preventing stroke and other vascular events in patients with vascular disease.Cochrane Database Syst Rev. 2003;(1):CD001820. doi: 10.1002/14651858.CD001820. Cochrane Database Syst Rev. 2003. Update in: Cochrane Database Syst Rev. 2006 Apr 19;(2):CD001820. doi: 10.1002/14651858.CD001820.pub2. PMID: 12535415 Updated.
-
Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation.Health Technol Assess. 2004 Oct;8(38):iii-iv, 1-196. doi: 10.3310/hta8380. Health Technol Assess. 2004. PMID: 15461876
-
Oral anticoagulants versus antiplatelet therapy for preventing further vascular events after transient ischaemic attack or minor stroke of presumed arterial origin.Cochrane Database Syst Rev. 2001;(4):CD001342. doi: 10.1002/14651858.CD001342. Cochrane Database Syst Rev. 2001. Update in: Cochrane Database Syst Rev. 2006 Jul 19;(3):CD001342. doi: 10.1002/14651858.CD001342.pub2. PMID: 11687110 Updated.
-
Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks.Cochrane Database Syst Rev. 2000;(2):CD001925. doi: 10.1002/14651858.CD001925. Cochrane Database Syst Rev. 2000. Update in: Cochrane Database Syst Rev. 2005 Oct 19;(4):CD001925. doi: 10.1002/14651858.CD001925.pub2. PMID: 10796452 Updated.
-
Antiplatelet agents and anticoagulants for hypertension.Cochrane Database Syst Rev. 2004;(3):CD003186. doi: 10.1002/14651858.CD003186.pub2. Cochrane Database Syst Rev. 2004. Update in: Cochrane Database Syst Rev. 2011 Dec 07;(12):CD003186. doi: 10.1002/14651858.CD003186.pub3. PMID: 15266473 Updated.
Cited by
-
Network meta-analysis on the efficacy and safety of finerenone versus SGLT2 inhibitors on reducing new-onset of atrial fibrillation in patients with type 2 diabetes mellitus and chronic kidney disease.Diabetol Metab Syndr. 2022 Oct 27;14(1):156. doi: 10.1186/s13098-022-00929-3. Diabetol Metab Syndr. 2022. PMID: 36303247 Free PMC article. Review.
-
Screening for atrial fibrillation: the role of CHA2DS2-VASc and atrial fibrillation burden.Eur Heart J Suppl. 2024 Jul 31;26(Suppl 4):iv41-iv49. doi: 10.1093/eurheartjsupp/suae078. eCollection 2024 Jul. Eur Heart J Suppl. 2024. PMID: 39099574 Free PMC article.
-
Risk factors for stroke and choice of oral anticoagulant in atrial fibrillation.Eur J Clin Pharmacol. 2018 Dec;74(12):1653-1662. doi: 10.1007/s00228-018-2540-3. Epub 2018 Aug 16. Eur J Clin Pharmacol. 2018. PMID: 30116828
-
Stroke prevention in the high-risk atrial fibrillation patient: Medical management.Curr Cardiol Rep. 2011 Feb;13(1):9-17. doi: 10.1007/s11886-010-0148-z. Curr Cardiol Rep. 2011. PMID: 20953740 Review.
-
Effect of atrial fibrillation in Asian patients undergoing percutaneous coronary intervention with drug-eluting stents for stable coronary artery disease: Results from a Korean nationwide study.Medicine (Baltimore). 2018 Nov;97(48):e13488. doi: 10.1097/MD.0000000000013488. Medicine (Baltimore). 2018. PMID: 30508978 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical